Lung survival rate

Surgical resection of the tumor is the mainstay of treatment in early-stage non-small cell lung cancer and produces the longest survival rates. 

Small cell lung cancer typically presents as extensive disease (approximately 60% to 70% of new cases) and progresses very quickly. Small cell carcinomas are very responsive to chemotherapy and radiation. Radiotherapy became the standard in 1969, when a randomized trial showed that it offered the potential for cure, whereas surgery did not.20 For the vast majority of patients, chemotherapy with or without radiotherapy is the treatment of choice. Even after a complete response to therapy, the cancer usually recurs within 6 to 8 months, and survival time following recurrence is typically short ( 4 months). This yields a typical survival rate of 14 to 20 months for limited disease and 8 to 13 months for extensive disease.33 Table 87-6 illustrates the general treatment path of SCLC. 

Long-Term (5 Years) Survival Rates of Lung Cancer Comparison of ECT with other Conventional Techniques"... 

DMN is clearly carcinogenic, producing tumors in a number of animal species at relatively low doses. Swiss mice fed a diet containing 0.005% DMN for 1 week developed tumors of the kidney and lung. Hamsters fed a diet containing 0.0025% for 11 weeks developed liver tumors. A consistent observation after oral administration of DMN in rats has been that long-term treatment with doses compatible with a favorable survival rate leads to liver tumors, whereas short-term treatment with high doses produces renal tumors. ... 

Takeda et al. (64) performed a phase I/II study consisting of low-dose CDDP (6-10 mg/m2/d) and UFT (600 mg/d) combined with radiotherapy (50 Gy/25 fractions) as postoperative adjuvant therapy following curative resection for patients with nonsmallcell lung cancer (NSCLC). The combined therapy was well tolerated and resulted in a disease-free survival rate of 78% at 2 yr. Another study in a small number of patients with unresectable stage III nonsmall-cell lung cancer, UFT (400 mg/m2 on d 1-52) and CDDP (80 mg/m2 on d 8,29, and 50) were administered with radiation therapy (total dose of 60.8 Gy in 38 fractions on d 1-52). Among 17 evaluable patients, 94% (16 patients) achieved partial responses with median time to tumor progression of 30 wk, and the... 

The earliest combination chemotherapy and radiation trials in nonsmall-cell lung cancer included cisplatin and 5-fluorouracil and concurrent radiation therapy and found survival results comparable to those for sequential chemotherapy and radiation or to daily cisplatin and radiation therapy without surgery (119,121). Phase II studies of stage Ilia and Illb nonsmall-cell lung cancer patients treated with the combination of cisplatin with etoposide and 5 -fluorouracil and either single daily radiation fractionation or twice daily radiation fractionation prior to surgery produced similar clinical results (119,121). Complete surgical resection was accomplished in 70% of the patients, the median survival was 22 mo and the 2-yr survival rate was 45%. 

There is certainly less data available on the role of concurrent docetaxel with radiation in the treatment of locally advanced nonsmall-cell lung cancer. Koukourakis et al. (66) have reported on their phase I/II experience of administering radiation concurrently with docetaxel for stage IIIB NSCLC. In the phase II portion of their study, 30 mg/m2 of docetaxel was given weekly with concurrent 64 Gy of thoracic radiation. Esophagitis was the main side effect of the regimen wherein 17% of patients needed a two-week treatment delay and another 31 % of patients required minor delays (3-7 d). Thirty-five patients were enrolled and evaluable, and the overall response rate was 80% (34% CR). The median survival was 12 mo, and 1-yr survival rate was reported as being 48%. 

The first combined heart-lung transplant was performed in 1981 at Stanford University. Combined heart-lung donors need to satisfy both the requirements already described separately. Combined heart-lung transplant is recommended in patients with congenital problems affecting these organs, pulmonary hypertension and/or cystic fibrosis. The recipients for the combined transplant are recommended to be less than 55 years old. Survival rates are 79, 66, and 54% at 1 month, 1 year and 3 years, respectively, after transplantation. 

The prognosis of SLE has much improved during recent decades. The overall 10-year survival rate in retrospective series is 75-85% (Ul). The major cause of early death is usually active disease, whereas the leading cause of late death is atherosclerosis (A2). Infection is a major cause of mortality in all stages of SLE (G16). In our experience with SLE in children, the 5-year renal and patient survival rates were 93.1% and 91.08%, respectively (Y4). Several features of SLE have been associated with mortality in a multivariate model (A3). These features include renal damage, thrombocytopenia, very active disease at presentation, and lung involvement. Despite the large decrease in the mortality of SLE patients, there are still many issues to be resolved (G16). 

These pure dextran phosphates exhibit immunostimulatory effects independent of the molecular weight. It was shown that the mitogenic response of murine splenocytes can be enhanced [101]. Moreover, dextran phosphate (Mw 40 000 g mol-1) increases the survival rate of mice infected with influenza A2 virus (H2N2). Intraperitoneal administration of dextran phosphate, an interferon inducer, shows a 1-day delay in the virus growth in lung, and production of HAI antibody, when compared to the non-treated or dextran-treated mice as controls. More significant was the 2-day delay in the development of lung consolidation, which led to 40% survival of the treated mice [102]. 

In a murine model of virus-induced lung injury, erythromycin significantly improved survival rate (10). This may be explained by inhibition of inflammatory-cell responses and suppression of nitric oxide overproduction in the lungs of the virus-infected mice. 

Thujae occidentalis herb, Baptisiae tinctoriae root, E. purpurea root, and E. pallida root, were given to mice. After 6 days the mice were inoculated with Influenza virus Type A. They found a statistically significant increase in survival rate, survival time, reduced lung consolidation, and virus titer (14). 

Lung cancer is the leading cause of cancer deaths in both men and women in the United States. The overall 5-year survival rate for all types of lung cancer is approximately 15%. 

---